Company hVIVO plc

Equities

VENN

GB00B9275X97

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:00 2024-07-05 am EDT 5-day change 1st Jan Change
27.7 GBX +0.36% Intraday chart for hVIVO plc +2.78% +16.63%

Business Summary

hVIVO plc is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO plc runs challenge trials in London with a new 50 quarantine bedroom, state-of-the-art facilities opening in Canary Wharf in 2024, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

Number of employees: 274

Sales per Business

GBP in Million2022Weight2023Weight Delta
Contract Research Organisation Pharmaceutical Services
95.5 %
48 95.6 % 56 95.5 % +15.61%
Other
4.5 %
2 4.4 % 3 4.5 % +18.15%

Sales per region

GBP in Million2022Weight2023Weight Delta
United Kingdom, Ireland, France and Netherlands
100.0 %
51 100.0 % 59 100.0 % +15.72%

Managers

Managers TitleAgeSince
Chief Executive Officer 55 21-10-12
Founder 37 11-01-31
Founder 59 11-01-31
Director of Finance/CFO 61 17-06-30
Chief Tech/Sci/R&D Officer - 13-12-31
Chief Tech/Sci/R&D Officer - 14-03-31
Chief Tech/Sci/R&D Officer - 20-05-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 57 22-06-07
Founder 59 11-01-31
Founder 73 18-11-30
Director/Board Member 63 20-11-23
Chief Executive Officer 55 21-10-12
Director of Finance/CFO 61 17-06-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 680,371,877 391,922,887 ( 57.60 %) 0 57.60 %

Shareholders

NameEquities%Valuation
JPMorgan Asset Management (UK) Ltd.
7.038 %
47,887,547 7.038 % 16 M p
Canaccord Genuity Wealth Ltd.
3.983 %
27,099,500 3.983 % 9 M p
Octopus Investments Ltd.
3.528 %
24,005,475 3.528 % 8 M p
21,159,177 3.110 % 7 M p
20,702,209 3.043 % 7 M p
Gresham House Asset Management Ltd.
1.870 %
12,726,146 1.870 % 4 M p
Mandarine Gestion SA
0.6276 %
4,270,000 0.6276 % 1 M p
4,017,270 0.5905 % 1 M p
Margetts Fund Management Ltd.
0.0916 %
623,210 0.0916 % 212 652 p
Yamin Khan
0.0770 %
523,730 0.0770 % 178 707 p

Company contact information

hVIVO PLC

40 Bank Street Floor 24

E14 5NR, London

+

http://www.hvivo.com
address hVIVO plc(VENN)

Sales per Business

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.277 GBP
Average target price
0.3607 GBP
Spread / Average Target
+30.22%
Consensus

Annual profits - Rate of surprise